hs-CRP

A substantial share of heart attacks happen in people whose cholesterol looks fine. Something else is driving the damage, and one of the clearest culprits is quiet, low-grade inflammation in the walls of your arteries. hs-CRP (high-sensitivity C-reactive protein) is the blood test that can see it.

This is not a test for whether you feel inflamed. It is a test for the kind of inflammation you cannot feel, the kind that sits in the background for years and reshapes your risk of heart attack, stroke, and early death. Knowing your number gives you a lever that a standard cholesterol panel does not.

What hs-CRP Actually Measures

CRP is a protein your liver releases when your immune system detects inflammation anywhere in your body. Standard CRP tests were built to catch big spikes from infection or injury. hs-CRP uses a more sensitive method to detect very small amounts of the same protein, the amounts that hover in the background of a body that looks healthy but is not.

The molecule is the same. The difference is what the assay can see. Older CRP tests could not reliably detect the very low levels that matter for cardiovascular risk. hs-CRP fills in that blind spot.

This is one of the most persistent points of confusion. Patients and clinicians sometimes treat hs-CRP and standard CRP as different molecules. They are not. hs-CRP is CRP measured with better resolution at the low end of the scale.

Heart Attack and Stroke Risk

The strongest case for hs-CRP is cardiovascular. Across large studies of adults without known heart disease, higher hs-CRP predicts future heart attacks, strokes, and cardiovascular death even after adjusting for cholesterol, blood pressure, smoking, and diabetes.

In a study of 448,653 adults without known cardiovascular disease, those in the highest hs-CRP category had about 34% higher risk of major adverse cardiac events, 61% higher cardiovascular death, and 54% higher all-cause death compared with those in the lowest category. Adding hs-CRP to a standard European risk score improved risk reclassification by 14.1%. That reclassification matters because it is the size of the gap between people who look low-risk on paper and people who actually have a hidden inflammatory driver.

The most striking case is people whose LDL cholesterol looks acceptable. In the JUPITER trial, adults with acceptable LDL-C but elevated hs-CRP had about 44% fewer first major cardiovascular events (a composite including heart attack, stroke, cardiovascular death, arterial revascularization, and hospitalization for unstable angina) when treated with a statin. This is the population a standard lipid panel misses completely. The trial has caveats worth knowing: it did not include a low-LDL and low-hs-CRP comparison arm, so it cannot fully separate the benefit driven by hs-CRP from the benefit statins provide to at-risk adults more broadly.

Stroke and Long-Term Mortality

Higher hs-CRP also tracks with worse outcomes after stroke. In a meta-analysis of stroke patients, high admission hs-CRP was associated with roughly 3.8 times higher mortality after an ischemic stroke, about 1.9 times higher risk of a recurrent stroke, and about 1.8 times higher risk of poor recovery. Prediction of first-ever stroke in people without prior disease is less consistent, so hs-CRP is a stronger prognostic tool than a diagnostic one for stroke.

For overall mortality, the pattern is consistent. A meta-analysis of 83,995 participants comparing the highest to the lowest hs-CRP category found about twice the cardiovascular mortality risk, roughly 75% higher all-cause mortality, and about 25% higher cancer-related mortality.

Type 2 Diabetes and Kidney Disease

Inflammation and metabolic dysfunction are tightly linked. In a study of 927 adults with type 2 diabetes, those in the highest quarter of hs-CRP had roughly twice the odds of diabetic kidney disease compared with those in the lowest quarter, even after adjusting for blood pressure, weight, blood sugar control, and other lab values.

In people with chronic kidney disease not yet on dialysis, higher hs-CRP was associated with about twice the risk of death from any cause and about 63% higher risk of major cardiovascular events compared with lower hs-CRP. The kidney itself did not decline faster in that study, so hs-CRP in this group flags overall risk rather than direct kidney damage.

Beyond the Heart

hs-CRP goes up in many other conditions, which is why it is powerful but not specific. Hypertensive adults tend to have higher hs-CRP than those with normal blood pressure. People with hypothyroidism have shown higher average hs-CRP in case-control studies. Depressive symptoms have been linked to higher hs-CRP in large surveys, with one cross-sectional analysis showing about 10% higher odds of depression per unit increase in hs-CRP, and another finding a stronger association in younger adults.

The takeaway is not that hs-CRP diagnoses these conditions. It is that chronic inflammation reaches across many systems, and a number that is quietly high deserves a closer look at the broader picture, not just the arteries.

Reconciling the Nonspecificity

It is fair to ask how a marker can be so predictive of heart disease while also rising with infection, obesity, hormone therapy, and dozens of other conditions. The answer is that hs-CRP is best read as a general inflammation dial, not as a heart-disease-specific alarm. Chronic vascular inflammation is one of the loudest signals it picks up, but it is not the only one. A single high number tells you inflammation is present. Context, retesting, and the rest of your health picture tell you why.

This is also why major cardiovascular guidelines currently give hs-CRP a Class IIb recommendation, meaning it may be considered as part of risk assessment rather than being endorsed as a routine screening test. The 2025 ACC Scientific Statement on Inflammation and Cardiovascular Disease reflects a growing acceptance of hs-CRP's role, but treating your number as one input into a broader picture, rather than a standalone verdict, is the responsible framing.

Why One Reading Is Not Enough

hs-CRP moves. A meta-analysis of 60 studies found substantial within-person variation, with a median coefficient of variation around 0.44. That means the same person, measured across different days or weeks, can produce meaningfully different results without anything really changing about their long-term risk. A single reading can mislead you in either direction.

The evidence also suggests that repeated exposure to elevated hs-CRP matters more than any single value. In a large Chinese cohort, people who were persistently high across three separate measurements had significantly higher cardiovascular disease and heart attack risk than people who were only high once. Trend beats snapshot.

A sensible rhythm looks like this: get a baseline, retest in 3 to 6 months if you are actively changing something in your lifestyle, medications, or metabolic health, and continue at least annually after that. If a value comes back very high, do not treat it as a cardiovascular risk score. Recheck after about two weeks. Very high values usually reflect an acute inflammatory event, not chronic vascular risk.

When Results Can Be Misleading

hs-CRP is sensitive, which is its strength and also its weakness. Several situations can push a reading up without meaning your cardiovascular risk has actually changed.

• Recent infection or injury: acute illness, dental infection, or tissue trauma can push hs-CRP into the double digits for days to weeks. Very high values should be retested after about two weeks rather than interpreted as cardiovascular risk.
• Estrogen therapy: postmenopausal women taking oral estrogen-containing hormone replacement have been shown to run higher hs-CRP without a corresponding change in vascular biology.
• Obesity, smoking, and insulin resistance: these lift baseline hs-CRP through real metabolic inflammation, which is meaningful for risk but complicates interpretation as a purely cardiovascular signal. Analyses from the Dallas Heart Study and MESA suggest that obesity may account for a large portion of the observed relationship between hs-CRP and coronary atherosclerosis, which is worth keeping in mind if your BMI is high.
• Recent PCI or procedures: hs-CRP rises transiently after coronary procedures. In one study, levels jumped roughly three to four fold within 24 hours of elective PCI.
• Recent meals: while formal guidelines do not require fasting, one study in coronary heart disease patients found that a standard meal reclassified about a third of participants from lower to higher hs-CRP categories, so consistency in timing helps if you are tracking a trend.

What to Do If Your Number Is High

An unexpectedly high hs-CRP is not a diagnosis. It is a prompt to look more carefully. The first step is to confirm the result with a repeat test, ideally after enough time has passed that any acute illness or injury has cleared. Two weeks is a reasonable minimum.

Once you know the elevation is real, the next step is to look at what else is happening. If your LDL cholesterol, ApoB, blood pressure, or blood sugar are also drifting, the picture is coherent and points toward vascular risk. If everything else looks clean, hs-CRP may be flagging something outside the cardiovascular system, and further workup with your physician makes sense. In some cases involving unclear elevation, a cardiologist, endocrinologist, or lipidologist can help sort out whether the number reflects arterial risk, metabolic dysfunction, or a chronic condition worth investigating.

The pattern that most changes decisions is elevated hs-CRP with LDL cholesterol that looks acceptable. That combination is exactly what the JUPITER trial identified as high-yield for preventive therapy, and it is a scenario a standard lipid panel would let you walk past.